Bayer, Glaxo Find Steps Difficult Toward Better Margins In Consumer Product Space
This article was originally published in The Tan Sheet
Executive Summary
Glaxo and Bayer report second-quarter growth in consumer segment sales driven largely by the new parts of the businesses. GSK’s earnings report is its first since taking the helm of a consumer product JV with Novartis AG; Bayer’s is its second with Merck & Co.’s former consumer products brands in its lineup.
You may also be interested in...
Nonprescription Nasonex Gains UK Regulator’s Support
The UK MHRA is accepting comments on its recommendation to allow pharmacy sales of nonprescription Nasonex Allergy Control (mometasone furoate/100 mcg).
Nonprescription Nasonex Gains UK Regulator’s Support
The UK MHRA is accepting comments on its recommendation to allow pharmacy sales of nonprescription Nasonex Allergy Control (mometasone furoate/100 mcg).
Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.